These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9395152)

  • 1. Long-term outcome of depot neuroleptic maintenance treatment among chronic psychotic patients.
    Tuninger E; Levander S
    Acta Psychiatr Scand; 1997 Nov; 96(5):347-53. PubMed ID: 9395152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment.
    Morrissette DA; Stahl SM
    CNS Spectr; 2012 Nov; 17 Suppl 1():10-21. PubMed ID: 23462201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lowest effective dose of depot neuroleptics.
    Hoencamp E; Haffmans PJ; Jansen GS
    Br J Psychiatry; 1992 Mar; 160():422-3. PubMed ID: 1348655
    [No Abstract]   [Full Text] [Related]  

  • 4. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical predictors of relapse following neuroleptic withdrawal.
    Buchanan RW; Kirkpatrick B; Summerfelt A; Hanlon TE; Levine J; Carpenter WT
    Biol Psychiatry; 1992 Jul; 32(1):72-8. PubMed ID: 1356490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Large variations of plasma levels during maintenance treatment with depot neuroleptics.
    Tuninger E; Levander S
    Br J Psychiatry; 1996 Nov; 169(5):618-21. PubMed ID: 8932892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-acting injectable risperidone in treatment refractory patients: a 14-week open-label pilot study.
    Procyshyn RM; Barr AM; Flynn S; Schenk C; Ganesan S; Honer WG
    Schizophr Res; 2010 Nov; 123(2-3):273-5. PubMed ID: 20688481
    [No Abstract]   [Full Text] [Related]  

  • 8. Neuroleptic dose reduction in older psychotic patients.
    Harris MJ; Heaton RK; Schalz A; Bailey A; Patterson TL
    Schizophr Res; 1997 Oct; 27(2-3):241-8. PubMed ID: 9416653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of neuroleptic reduction in schizophrenic outpatients receiving high doses.
    Leblanc G; Cormier H; Gagné MA; Vaillancourt S
    Can J Psychiatry; 1994 May; 39(4):223-9. PubMed ID: 7913872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
    Citrome L; Jaffe A; Levine J
    Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study.
    Mayoral-van Son J; de la Foz VO; Martinez-Garcia O; Moreno T; Parrilla-Escobar M; Valdizan EM; Crespo-Facorro B
    J Clin Psychiatry; 2016 Apr; 77(4):492-500. PubMed ID: 26759992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroleptic dosing in chronic schizophrenia: a 10-year follow-up.
    Remington GJ; Prendergast P; Bezchlibnyk-Butler KZ
    Can J Psychiatry; 1997 Feb; 42(1):53-7. PubMed ID: 9040924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased Framingham 10-year risk of coronary heart disease in middle-aged and older patients with psychotic symptoms.
    Jin H; Folsom D; Sasaki A; Mudaliar S; Henry R; Torres M; Golshan S; Glorioso DK; Jeste D
    Schizophr Res; 2011 Feb; 125(2-3):295-9. PubMed ID: 21093219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.
    Parellada E; Andrezina R; Milanova V; Glue P; Masiak M; Turner MS; Medori R; Gaebel W
    J Psychopharmacol; 2005 Sep; 19(5 Suppl):5-14. PubMed ID: 16144781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of zuclopenthixol acetate on psychotic anxiety evaluated in an open study].
    Romain JL; Dermain P; Greslé P; Grignon S; Moisan P; Nore D; Pech G; Benyaya J; Perret I
    Encephale; 1996; 22(4):280-6. PubMed ID: 9035983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective 1-5 year outcome study in first-admitted and readmitted schizophrenic patients; relationship to heredity, premorbid adjustment, duration of disease and education level at index admission and neuroleptic treatment.
    Wieselgren IM; Lindstrom LH
    Acta Psychiatr Scand; 1996 Jan; 93(1):9-19. PubMed ID: 8919324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing the dose of depot neuroleptics in stable schizophrenia.
    Dale R; Longdon M; Seeman MV
    J Psychiatry Neurosci; 1994 Jul; 19(4):278-81. PubMed ID: 7918349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].
    Samalin L; Abbar M; Courtet P; Guillaume S; Lancrenon S; Llorca PM
    Encephale; 2013 Dec; 39 Suppl 4():189-203. PubMed ID: 24373464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bipolar episodes in adolescents: diagnostic issues and follow-up in adulthood].
    Cohen D; Guilé JM; Brunelle J; Bodeau N; Louët E; Lucanto R; Consoli A
    Encephale; 2009 Dec; 35 Suppl 6():S224-30. PubMed ID: 20141776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.